Premium
Ergot mesylates for alzheimer's disease: A year‐long double‐blind trial of 3 mg vs 12 mg daily
Author(s) -
Jenike Michael A.,
Albert Marilyn,
Baer Lee,
Gunther Jeanette,
Corvino Christine
Publication year - 1990
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/gps.930050605
Subject(s) - dose , double blind , mood , medicine , significant difference , anesthesia , pediatrics , psychiatry , placebo , alternative medicine , pathology
Abstract Of 25 patients who entered a year‐long double‐blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylates (Hydergine), 17 completed the full year of study and no patients suffered problematic side‐effects. On a number of complex tests of memory function, there was no difference between the patients receiving low‐dose versus high‐dose Hydergine. There were also no significant between‐group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.